SCHEMBL18296261

SCHEMBL18296261

COc1cccc(-c2cc(=O)c3c(O)c(OC)ccc3[nH]2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 3/20 0.54
HPGD P15428 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.51
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51
TUBB3 Q13509 1/20 0.51
TUBB2A Q13885 1/20 0.51
TUBB8 Q3ZCM7 1/20 0.51
TUBA3E Q6PEY2 1/20 0.51
TUBA1A Q71U36 1/20 0.51
TUBA1C Q9BQE3 1/20 0.51
TUBB6 Q9BUF5 1/20 0.51
TUBB2B Q9BVA1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31740462 0.87 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL340206 0.87 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL18294601 0.85 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL339610 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL31237652 0.77 ALDH1A1 (0.82) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL340236 0.76 CYP1A1 (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2TUBB4A
SCHEMBL8980413 0.75 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL30462987 0.74 HPGD (0.74) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL340201 0.73 ALDH1A1 (0.65) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL18084363 0.73 HPGD (0.56) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302488-B1 NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY TAIRX INC (TW) 2020-09-30 EP disclosed
US-9717721-B2 Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry TAIRX, INC. (TW) 2017-08-01 US disclosed
US-20160354361-A1 NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY TAIRX INC. (TW) 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354361-A1 NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY TEK, FLT1, VHL ALDH1A1 1091/4885KDM4E 1014/4885HPGD 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.